0.29
-0.01 (-3.69%)
0.3003
+0.01 (+3.55%)
Taking everything into account, KLDO scores 1 out of 10 in our fundamental rating. KLDO was compared to 190 industry peers in the Pharmaceuticals industry. KLDO may be in some trouble as it scores bad on both profitability and health. KLDO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- KLDO had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -180.08% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- KLDO does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | -8155.92% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for KLDO has been increased compared to 1 year ago.
- The debt/assets ratio for KLDO is higher compared to a year ago.
2.2 Solvency
- KLDO has an Altman-Z score of -15.43. This is a bad value and indicates that KLDO is not financially healthy and even has some risk of bankruptcy.
- A Debt/Equity ratio of 0.52 indicates that KLDO is somewhat dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.43 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.43 indicates that KLDO should not have too much problems paying its short term obligations.
- KLDO has a Quick Ratio of 1.43. This is a normal value and indicates that KLDO is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.43 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 11.65% over the past year.
- KLDO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.12%.
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.48%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%105%
3.2 Future
- KLDO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.99% yearly.
- KLDO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 252.50% yearly.
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- KLDO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year KLDO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.05 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.33%
EPS Next 3Y4.15%
5. Dividend
5.1 Amount
- KLDO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KALEIDO BIOSCIENCES INC / KLDO FAQ
Can you provide the ChartMill fundamental rating for KALEIDO BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 2 / 10 to KLDO.
What is the valuation status of KALEIDO BIOSCIENCES INC (KLDO) stock?
ChartMill assigns a valuation rating of 3 / 10 to KALEIDO BIOSCIENCES INC (KLDO). This can be considered as Overvalued.
How profitable is KALEIDO BIOSCIENCES INC (KLDO) stock?
KALEIDO BIOSCIENCES INC (KLDO) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for KLDO stock?
The Earnings per Share (EPS) of KALEIDO BIOSCIENCES INC (KLDO) is expected to grow by 10.24% in the next year.